Clinical Trial Update: Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS. [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 clinical trial evaluated maximum heart rate after ReConnect supplementation versus placebo in Chronic Fatigue Syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fatigue Syndrome

Drugs mentioned

• ReConnect

Snippet

Sponsor: Hospital Universitari Vall d'Hebron Research Institute | Conditions: Chronic Fatigue Syndrome | Phase 2, Phase 3 | Status: COMPLETED